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Do people with mental illness receive adequate smoking cessation advice? A 
systematic review and meta-analysis 
Abstract 
Background: Prevalence rates of smoking in people with mental illness are high and premature 
mortality attributed to tobacco related physical comorbidity is a major concern.  We conducted a 
meta-analysis comparing rates of receipt of smoking cessation advice among people with and 
without mental illness.   
 
Method: Major electronic databases were searched from inception till August 2014 for studies 
comparing rates of receipt of smoking cessation advice of people with and without a mental illness. 
Two independent authors completed methodological appraisal and extracted data. A random effects 
meta-analysis was utilized. 
 
Results: Seven studies of satisfactory methodological quality (n mental illness= 68,811, n 
control=652,847) were included. Overall there was no significant difference in smoking cessation 
advice rates between those with and without a mental illness (RR=1.02, 95% CI: 0.94 – 1.11-, 
n=721,658, Q=1421, p<0.001).  Subgroup analyses demonstrated people with severe mental illness 
(SMI) received comparable rates of smoking cessation advice to those without SMI (RR=1.09, 95% CI 
0.98-1.2, n=559,122).  This remained true for people with schizophrenia (RR=1.09, 95% CI 0.68-1.70) 
and bipolar disorder (RR=1.14, 95% CI 0.85-1.5).  People with non-severe mental illnesses were 
slightly more likely to receive smoking cessation advice (RR=1.16, 95% CI=1.04-1.30, Q=1364, 
p<0.001, n=580,206). 
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Conclusions:  People with SMI receive similar smoking cessation advice rates as people without 
mental illness, whilst those with non-severe mental illness are slightly more likely to receive smoking 
cessation advice. Whilst progress has been made, offering smoking cessation advice should receive a 
higher priority in everyday clinical practice for patients with a mental health diagnosis.  
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Introduction 
There is irrefutable evidence that people with mental illness have a reduced life expectancy 
compared to members of the general population 1-3. Worryingly, this mortality gap appears to be 
widening 3,4. About 80% of these deaths are attributable to physical comorbidity and modifiable 
lifestyle factors rather than suicide 1-3,5.  For instance, Lawrence et al 3 recently established in a large 
population based study that 77.7% of deaths were attributed to physical health comorbidity such as 
cardiovascular disease (29.9%) and cancer (13.5%).   
One modifiable lifestyle factor that is consistently implicated as a contributory factor to this 
mortality gap is smoking 2,3,6. Smoking is the most common substance use disorder in people with 
mental illness and prevalence rates are two to four times higher than members of the general 
population 7-9.  In the USA, people with mental illness are estimated to smoke almost one out of 
every two cigarettes smoked 7,9,10. People with severe mental illness (SMI) are particularly at risk and 
are often very heavy smokers 9 and in particular it has long been known that people with 
schizophrenia smoke at high rates and this remains true today.  For instance, Hartz et al 11 recently 
established that people with schizophrenia are substantially much more likely to smoke than the 
general population (Odd Ratio=4.6). It is therefore unsurprising that mortality attributed to smoking 
is particularly high among this group. For example, Tran et al 12 found that smoking is associated with 
a two fold increase in cancer related deaths in those with mental illness. Others have found that 
mortality is higher in smokers than non-smokers with schizophrenia (Hazard Ratio=2.1) with around 
12 times increased risk of cardiac death seen in patients aged 35-54 13. Cardiac disease accounted for 
43% of deaths in smokers but only 19% of deaths in non-smokers with schizophrenia 13 thus 
indicating the increased risk of cardiovascular disease when patients smoke.  Moreover, it is 
estimated that quitting smoking might reduce cardiac events by 90% in this group 14. However, 
smoking related mortality affects all people with mental illness, regardless of diagnosis. Callaghan et 
al 15 found in a large scale follow-up study covering approximately 1.7 million years that tobacco 
related conditions accounted for roughly 53% of total deaths in schizophrenia, 48% in bipolar 
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disorder and 50% of those with depression. Overall, estimates seem to suggest that life expectancy 
among people with mental illness is reduced by approximately 25 years due to chronic diseases 
secondary to tobacco use (e.g., cardiac and pulmonary disease, 16) compared to 10 years among 
smokers without a mental illness 17. The economic costs associated with smoking among people with 
mental illness are also considerable. For instance, in the United Kingdom the cost to the economy for 
smokers with mental illness was estimated to be £2.34 billion in 2009/10 18 (approximately $3.74 
billion) including direct healthcare costs, indirect morbidity costs and indirect mortality costs due to 
smoking-related diseases.   
Given the above, numerous authors have called for urgent research to determine and 
deliver effective smoking cessation interventions among people with mental illness in daily clinical 
practice 3,9,15. Helping people with mental illness stop smoking should form a routine part of clinical 
care and is clearly an International public health priority 19 and several interventions may help. For 
instance, a systematic review of randomised control trials on smoking cessation interventions 20 
established a number of safe approaches (for example Bupropion) to help people with schizophrenia 
stop smoking. A recent systematic review concluded that smoking cessation interventions are as 
effective in people with SMI as the general population 21. From an environmental perspective many 
inpatient psychiatric units have implemented smoking restrictions or bans 22. Whilst it is true that 
inconsistencies in the implementation of smoke-free policies in mental health facilities have been 
reported in a number of countries results have generally been encouraging 23. However the most 
fundamental intervention is smoking cessation advice. In the general population smoking cessation 
advice helps improve quit rates 24-26 but it remains unclear if this applies in mental health settings, in 
particular do such patients receive adequate cessation advice from clinicians? Mass media 
campaigns have been widely disseminated in many countries and may be effective for some groups 
27 but have not been aimed at those with mental illness. Thus despite some advances in awareness 
and interventions for smoking in those with mental ill heath it is not clear if we have achieved at 
least parity of care compared with the general population.  Advice and support to stop smoking from 
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members of the multidisciplinary team should be the first port of call and may instigate the process 
of stopping smoking for the patient.  
Within recent years, numerous studies have established that people with mental health 
problems receive suboptimal medical care as well as preventive advice and physical health screening 
compared to the general populations 28-31. It is currently unclear if these disparities extend to receipt 
of smoking cessation advice and support. Given the substantial burden of smoking on morbidity and 
mortality among people with mental illness, it is important that research considers if there is a 
disparity among smoking cessation advice given to people with mental illness compared to the 
general population, ideally whilst taking into account different subtypes and severity of mental ill 
health.  Thus, the aim of the current paper was to establish if there are differences in the rates of 
smoking cessation advice among people with mental illness compared to those without mental 
illness.   
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Method 
We conducted a systematic review and meta-analysis in accordance with the Meta-analysis of 
Observational Studies in Epidemiology guidelines 32 and reported it in line with the PRISMA 
statement 33 following a predetermined protocol.   
Eligibility criteria 
Studies were eligible that: 1) included people with a diagnosis of non-organic mental illness 
(including SMI (e.g. schizophrenia, psychosis, bipolar disorder), mood disorders, depression, anxiety) 
or mental health problem according to recognised diagnostic criteria (ICD 10 or DSM IV)/ validated 
screening measures or medical chart reviews.  2) Were comparative studies (including observational 
or intervention studies, in which case baseline data was used) with a group without mental illness. 3) 
Reported smoking cessation advice rates for both samples among those who smoked.  We defined 
smoking cessation advice in accordance with Stead et al 34 ;ϮϬϭϯͿ as ͚recorded verbal instructions 
froŵ the physiciaŶ ǁith a ’stop sŵokiŶg’ ŵessage irrespectiǀe of ǁhether or Ŷot iŶforŵatioŶ ǁas 
provided about the harmful effects of smoking͛.  We also iŶĐluded studies that ƌepoƌted sŵokiŶg 
cessation advice from any member of the multidisciplinary team, as we believe smoking cessation 
adǀiĐe is eǀeƌǇ ĐliŶiĐiaŶ͛s ƌespoŶsiďilitǇ. 
We did not include studies reported among people with dementia/ mild cognitive impairment or 
learning disabilities (although to our knowledge no such papers existed). No language restrictions 
were placed upon potentially eligible studies. If we encountered multiple studies from the same data 
set at different times, we used the largest and / or most recent data. If we encountered studies that 
enquired about smoking cessation advice but did not report the data in the paper, we contacted the 
authors to acquire the variables of interest (no additional requests were necessary).  .   
Literature search and study selection 
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Two independent authors (AJM, BS) conducted electronic searches of Medline, Pubmed, Embase 
and CINAHL electronic databases from inception till August 2014. The key words used were 
smoking* or smoking cessation or smoking cessation advice and mental or psychiatr* or depression 
or mood or anxiety or severe mental illness/ SMI or schizophrenia or psychosis or psychotic. In 
addition, we conducted full text searches of the Web of knowledge, Scopus, Science Direct, Ingenta 
Select, Springer-Veƌlag͛s LINK aŶd BlaĐkǁell WileǇ aŶd haŶd seaƌĐhed all iŶĐluded aƌtiĐles ;i.e. 
ĐheĐked the ƌefeƌeŶĐe lists foƌ poteŶtiallǇ ƌeleǀaŶt aƌtiĐlesͿ. We also ĐoŶduĐted oŶliŶe ͚haŶd 
seaƌĐhes͛ iŶĐludiŶg the iŶ pƌess sections of major psychiatric journals from 2000 up until August 
2014 (including General Hospital Psychiatry, British Journal of Psychiatry, Schizophrenia Research, 
Schizophrenia Bulletin, Psychological Medicine, Acta Psychiatrica Scandinavica, American Journal of 
Psychiatry, JAMA Psychiatry, Canadian Journal of Psychiatry, Journal of Psychiatric Research, 
Psychiatric Services).   
After the removal of duplicates, two independent reviewers (BS, AJM) screened the titles and 
abstracts of all potentially eligible articles. Both authors applied the eligibility criteria, and a list of 
full text articles was developed through agreement. Two reviewers (BS, AJM) then considered the 
full texts of these articles and the final list of included articles was reached through consensus.   
Methodological quality assessment 
Two authors (AJM, BS) independently completed the methodological appraisal of included studies 
using the Newcastle Ottawa Scale (NOS, 35). The NOS provides an assessment of the quality of non-
randomised controlled trials and each article received a methodological quality score out of 9. 
Articles were judged across three key areas: selection, comparability and outcomes. The NOS validity 
and reliability has been established and scores of 5 out of 9 were considered satisfactory quality 35.   
Data extraction 
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All data extraction was conducted by two independent authors (BS, AJM) utilising a predetermined 
form. We extracted data regarding the study design, setting, patient information (number, 
demographic, type of mental illness and classification criteria), control participant information, 
details of the smoking cessation advice and the results.   
Meta-analysis 
We calculated the relative risk (RR) together with the 95% confidence intervals (CI) for each study.  If 
we encountered odds ratios within the eligible papers, these were converted into RR using an 
established method 36. We planned subgroup analysis to compare smoking cessation advice rates in 
people with SMI (schizophrenia, bipolar disorders) and non-severe mental illnesses (e.g. depression, 
anxiety etc) as well as specific mental disorders.  Due to the anticipated heterogeneity, data was 
with a random effects meta-analysis 37. Heterogeneity was calculated with the Cochran Q statistic 38.  
All data was analysed using statsdirect software. Publication bias in each of the analyses was 
assessed ǁith a ǀisual iŶspeĐtioŶ of fuŶŶel plots aŶd Eggeƌ͛s ƌegƌessioŶ ŵethod 39 and Begg-
Mazumdar test 40, with a p-value <0.05 suggesting the presence of bias.   
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Results 
Search results, included studies and participant characteristics 
The initial searches yielded 1,103 valid hits and we subsequently screened the abstracts of 460 
papers. Following this, 386 papers were excluded and we considered the full texts of 74 potential 
articles. At this stage, the eligibility criteria were applied and 67 articles were excluded with reasons 
(see figure 1 for details) and 7 met the inclusion criteria.  Full details of the search strategy are given 
in figure 1.   
Figure 1 here 
Details of included studies  
In total, 721,658 participants were represented across the 7 cross-sectional studies including 
652,847 people without a mental illness and 68,811 people with a mental illness.  The mean age of 
people with mental illness across the studies ranged from 50.1 years to 76.1.  Four of the studies 
were conducted in the United States 41-44 and 3 were conducted in the United Kingdom 45-47.  A range 
of different types of mental illness were considered within the studies but 5 provided data for 
individuals with SMI (mainly schizophrenia and bipolar disorder; 42,43,45-47) and 4 provided data for 
people with other types of mental illness 41,43,44,47.  The type of smoking cessation advice varied, with 
2 studies this included counselling 41,42 and the remainder included general advice on smoking 
cessation and this was usually delivered by a physician.  Full details of the included studies are 
summarised in table 1.   
Table 1 here 
Methodological quality of the included studies 
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The NOS summary scores for each article are presented in table 1. No study scored below 5 on the 
NOS and all were considered at least of satisfactory methodological quality. Overall the mean NOS 
score across the 7 articles was 7.1±0.8.   
Narrative results  
Druss et al 41 included 88,241 patients from a national cohort and found no difference in smoking 
cessation counselling rates between those with a mental illness (n=4664) and without (n=83,577) 
(RR=1.03, 95% CI: 0.95-1.12). The authors 41 reported that attendance of smoking cessation 
counselling was associated with a reduced mortality across the entire population sample regardless 
of a mental health diagnosis or not (HR, 0.67; 95% CI, 0.62-0.72).  Hippisley-Cox et al 45 conducted a 
cross-sectional analysis with 485 general practices contributing anonymised medical records of over 
3.26 million patients to the database which included 127,932 patients with coronary heart disease 
(CHD) (701 had a diagnosis of schizophrenia or bipolar disorder). Overall, the study established there 
was not any significant difference in smoking cessation advice over the past 15 months for 
individuals with schizophrenia (RR=0.99 (95% CI: 0.95-1.04)) whilst there was a small but significant 
increased chance of people with bipolar disorder receiving smoking cessation advice (RR=1.04 (95% 
CI:1.01-1.07).   
Using a general practitioner database record linkage system, Whyte et al 46 did not find any 
significant difference in the rates of smoking cessation advice given to those with people diabetes 
and SMI (n=1043) and without any mental illness (n=10,000) (RR=1.52 (95% CI: 0.6-3.86)). Goldberg 
et al 42 compared smoking cessation counselling rates of care for type 2 diabetes delivered to those 
with SMI (n=201) and without (n=99) and found no significant difference (RR=1.96 (95% CI: 0.97-
3.95)) despite the significantly higher rates of smoking in the SMI group (53% compared to 34%).  
Szatkowski and McNeil 47 investigated the smoking cessation support including 387,246 primary care 
patients without a mental illness that smoked and 32,154 patients with a mental illness who 
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smoked.  Across the whole sample, there people with mental illness were significantly more likely to 
receive smoking cessation advice (RR=1.45 (CI: 1.43-1.48)) and this was evident in the subgroup 
analysis for all of the different types of mental illness except those with eating disorder. However, 
interventions appear lower per consultation for smokers experiencing mental illness when 
compared with smokers without.  Further details can be seen in table 1.   
Duffy et al 43 determined rates of smoking and receipt of provider recommendations for smoking 
cessation advice among patients with mental illness treated in the U.S. Department of Veterans 
Affairs (VA) treatment facilities. The authors demonstrated that people with schizophrenia who 
smoked (n=1430) were significantly less likely to be given smoking cessation advice from their 
physician compared to the general population (RR=0.69 (95% CI: 0.58-0.82). No significant 
differences were observed in smokers with bipolar disorder, other psychoses, people with 
depression and post-traumatic stress disorder. However, people with substance use disorders were 
significantly more likely to receive smoking cessation advice (RR=1.04 (CI: 102-1.05)). The authors 
found that the majority of patients with mental illness that reported receiving smoking cessation 
services still continued to uphold high smoking rates and that selected groups were at risk for 
receiving fewer smoking cessation services, indicating the continued need to distribute cessation 
services. Finally, Shi et al 44 found that overall people reporting mental health problems (n=1,897) 
were significantly more likely to receive smoking cessation advice (RR=1.22 (CI: 1.17-1.26)) than 
those without a mental illness (n= 17,042). 
Meta-analysis 
It was possible to pool the smoking cessation advice rates from 7 studies using 13 different samples 
(n=721,658).  Overall, there was no significant difference in smoking cessation advice rates between 
those with and without a mental illness (RR=1.02, 95% CI: 0.94 – 1.11, n=721,658, Q=1421, p<0.001; 
figure 2a).  The funnel plot was broadly symmetrical and neither the Begg (=0.205, P = 0.36) or the 
Egger test (=-2.27, P = 0.68) indicated any evidence of publication bias (figure 2b). 
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Figure 2 a and b here 
Smoking cessation advice rates among people with SMI 
Next, it was possible to pool smoking cessation advice rates from 5 studies incorporating 9 samples 
with individuals with SMI including a total of 559,122 participants (n SMI=6894, n control =552,228). 
The pooled analysis demonstrated there was no significant difference in smoking cessation advice 
rates between people with a SMI and those without an SMI (RR=1.09, 95% CI = 0.98 - 1.230; Q=242, 
p<0.001; figure 2).  The pooled analysis did not demonstrate any evidence of publication bias (Begg = 
0.11, p=0.61, Eggers test = 2.21, p=0.5). 
Figure 3 here 
We pooled data from 3 studies 43,45,47 to investigate if there were difference in smoking cessation 
advice rates in people with bipolar disorder and schizophrenia and the control populations.  The 
random effects analysis demonstrated there were no significant differences in smoking cessation 
rates in people with bipolar disorder (RR=1.14 (95% CI = 0.85-1.545; Q=109,p<0.001) or 
schizophrenia (RR=1.09 (95% CI = 0.68- 1.70; Q=109, p<0.001) compared to the control samples.   
Smoking cessation rates among people with non-severe mental illness 
Finally, it was possible to pool from 4 studies using 10 samples to investigate smoking cessation 
advices rates among people with and without a mental illness. The pooled analysis demonstrated 
that people with non-SMI were significantly more likely than control populations to receive smoking 
cessation advice (RR=1.16, 95% CI = 1.04-1.30; Q=1364, p<0.001, n mental illness=64,689, n 
control=515,517, figure 4). There was no evidence of publication bias within this analysis (Begg=0.15, 
P = Ϭ.ϲϬ, Eggeƌ test=ϱ.ϳϬ, =p=Ϭ.ϰͿ.  FiŶallǇ, tǁo studies ĐoŶsisted of ͞aŶǇ ŵeŶtal illŶess͟ aŶd ŵaǇ 
have included people with SMI; therefore we conducted an exploratory analysis removing these.  
This established that people with any non SMI mental illness were still significantly more likely to 
receive smoking cessation advice (RR=1.18, 95% CI = 1.04-1.33, Q=1331, p<0.001).   
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Insert figure 4 here 
 
Discussion 
This is the first meta-analysis to our knowledge to investigate if there is a disparity in smoking 
cessation advice rates in people with mental illness compared to the general population. Our results 
demonstrate that overall people with mental illness (including SMI) are broadly offered comparable 
rates of smoking cessation advice to members of the general population (RR=1.02, 95% CI 0.94-
1.11). Our subgroup analysis demonstrated that people with SMI are offered comparable rates 
(RR=1.10, 95%CI 0.98-1.23), whilst people with non SMI mental illness are offered slightly higher 
rates of smoking cessation advice rates (RR=1.16, 95%CI 1.04-1.30). Clearly, a broadly comparable 
level of cessation advice could remain a concern given the greatly increased smoking rates among 
people with mental illness and the physical illnesses and premature mortality directly attributable to 
smoking in people with mental illness.  Whilst progress has been made, equivocal interventions may 
not enough for this highly at risk population that has competing problems such as low socio-
economic status, poor social support, and comorbid substance abuse.  More intensive, multi-faceted 
interventions may need to be developed to reach this vulnerable population. This effect appeared to 
hold true even in those with schizophrenia alone and in those with bipolar illness alone (RR=1.09, 
95%CI 0.68-1.77 and RR=1.14, 95% CI 0.85-1.54 respectively). Only in cases of non-severe mental 
illness were rates higher and then only modest so by about 16%.   
Smoking cessation interventions are broadly as effective in people with mental illness, including 
those with SMI, as with members of the general population 21.  Therefore a failure to offer 
significantly greater levels of advice cannot be ascribed to therapeutic apathy. That said surveys of 
mental health professionals suggest only a minority feel that patients' smoking was their 
responsibility or would make time to treat smoking 48. Yet both the American and European 
Psychiatric Associations recommend it as a frontline clinical intervention 9,49.  The findings from 
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Druss et al 41 add ǁeight to the ͞ĐoŵŵoŶ seŶse͟ ƌeĐoŵŵeŶdatioŶ that ŵultidisĐipliŶaƌǇ teaŵs 
(MDT) should encourage, advise and support patients to stop smoking since they found across their 
whole sample (including 4664 people with mental illness) attendance at smoking cessation was 
associated with a greatly reduced mortality (HR=0.67). In the past there have been concerns echoed 
that encouraging individuals with mental illness may have a detrimental effect on their psychiatric 
symptoms. However, recent research 21 has established that provided the patients mental health 
status is stable, the provision of smoking cessation advice and initiation of treatment does not 
worsen their mental state. In fact, recent research has demonstrated that smoking cessation is 
actually associated with a risk reduction for mood/anxiety or alcohol use disorder, including those 
with these as pre-existing disorders 50. Since people with mental illness experience a wide range of 
barriers to stopping smoking 9 it is important that members of the MDT take the lead and give advice 
(including counselling) to instigate, educate, motivate and empower people with mental illness to 
stop smoking 9.   
Within our review, three studies were conducted in the UK where there has been a financial 
iŶĐeŶtiǀe foƌ geŶeƌal pƌaĐtitioŶeƌs ;GP͛sͿ to ƌeĐoƌd people ǁith ŵeŶtal illŶess sŵokiŶg status aŶd 
offer and implement smoking cessation services. This may have to some extent influenced the 
results in these countries, although they appear broadly similar to the other studies conducted in the 
US. It should also be noted that the US has also seen considerable smoking cessation efforts in the 
VA which may have accounted for this result 51.  Yet a direct comparison of cardiovascular screening 
(blood pressure, lipid levels and smoking status) of patients with asthma, and diabetes with patients 
with schizophrenia indicates that general practitioners are less likely to screen patients with 
schizophrenia for cardiovascular risk compared with the other two groups 52. Another important 
consideration of the results from this review is that several of these studies (e.g. 41,42,45,46) specifically 
recruited people with pre-existing physical comorbidities (diabetes or CHD). Whilst smoking 
cessation advice is a relatively new concept among people with mental illness, it is established 
among people with diabetes and CHD and this may have influenced the advice rates recorded. 
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Therefore, the smoking cessation advice rates observed in these studies is likely to be due to a 
greater sensitivity among providers to the poorer physical health of this group. It remains however 
unclear if smoking cessation advice rates and support are comparable in people newly diagnosed 
with a mental illness. Future research should consider people experiencing their first-episode of 
psychosis, since a previous meta-analysis 53 has already demonstrated significantly higher rates of 
smoking compared with the general population early in the disease.   
Clinical implications 
The receipt of higher rates of smoking cessation advice in non SMI is initially encouraging, although it 
is in reality small and clearly not entirely satisfactory.  It is concerning that in more severe forms of 
mental illness rates of received advice are often lower than in milder forms. There is strong evidence 
from previous studies that patients with schizophrenia and bipolar disorder receive inadequate 
medical care which may influence health outcomes such as mortality 29. We suggest failure to offer 
enhanced smoking cessation advice could be one factor maintaining high mortality in SMI. Provision 
of lifestyle advice within the psychiatric consultation is now promoted as a matter of routine 5, but 
our findings do indicate that advice on smoking may still not be offered systematically to all with 
mental illness that smoke. Because smoking cessation rates following interventions and advice are 
comparably effective with those observed in the general population, we believe that smoking 
cessation advice and associated therapeutic interventions and drug treatment are promoted by 
ŵeŶtal health MDT͛s.  The ĐuƌƌeŶt ƌeǀieǁ fiŶdiŶgs ĐleaƌlǇ deŵoŶstƌate that it is iŵpoƌtaŶt to giǀe 
psychiatrists, but also primary care physicians training in smoking cessation advice in people with 
mental illness. The treatment of tobacco dependence should for example be incorporated into the 
catalogue of disorders to be studied during specialist training in psychiatry.  However, offering 
smoking cessation advice should not be isolated to qualified doctors and all members of the MDT 
and in particular nurses may help in this process. 
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The American 49 and European 9 Psychiatric Associations recommend that psychiatrists should 
ƌoutiŶelǇ assess a patieŶt͛s sŵokiŶg status ;e.g., ĐuƌƌeŶt sŵokeƌ, eǆ-smoker, never smoked, number 
of cigarettes per day). A procedure analogous to the so-Đalled ͚ϰ A IŶteƌǀeŶtioŶ͛ ŵaǇ ďe 
recommended for short-term interventions: (1) Ask; (2) Advise; (3) Assist; (4) Arrange.  Treating 
psǇĐhiatƌists should thus: ;ϭͿ ask aďout the patieŶt͛s sŵokiŶg haďits; ;ϮͿ ĐleaƌlǇ adǀise the patieŶt to 
quit smoking; (3) offer the patient psychological support during smoking cessation and explain 
pharmacological aids; and (4) arrange follow-up visits to check that the patient is still abstinent.  
Otheƌ adaptatioŶs to this ŵodel, iŶĐludiŶg the ϱA͛s aƌe also aǀailaďle aŶd ĐaŶ ďe ĐoŶsideƌed 54.  
Previous research in 156 persons with SMI demonstrated that implementing (some of) these steps at 
each patient visit in community mental health centres may already have modest benefits (i.e. 
reduction of numbers of smokers and/or numbers of cigarettes smoked) after twelve months 55. 
Clinician advice to discontinue smoking is best given in a non-judgmental, empathic and supportive 
manner 56. A ͚Ƌuit daǇ͛ should ďe set oƌ gƌadual ƌeduĐtioŶ of toďaĐĐo ĐoŶsuŵptioŶ Đould ďe 
proposed as an alternative approach 57, especially as this method was recently found to have a 
comparable abstinence effect to quitting abruptly 58. Thus, both methods can be recommended. To 
increase the quit rate, established programmes (individual therapy, group therapy, telephone 
coaching) should however be employed wherever available 56. 
Limitations 
Whilst this is the first review of its kind, a number of limitations must be considered along with the 
results which are reflections of limitations in the primary studies. First, we pooled data on several 
different types of mental illness within the main analysis.  However, this is reflective of the range of 
mental illnesses seen by mental health services. We attempted to increase clinical homogeneity by 
conducting subgroup analysis for those with and without SMI and further attempted to reduce 
heterogeneity within these subgroup analyses. Second, it is unsurprising to note that each of the 
analysis demonstrated statistical heterogeneity.  Third, all of the studies included within the meta-
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analysis were from the UK or the US and it remains unclear if the results are generalizable outside 
these countries.  Fourth, most of the studies included older and people with mental illness (over 50 
years of age) that had pre-existing physical comorbidities (e.g. diabetes and CHD) and no data is 
available on people newly diagnosed with mental illness.  This means it is likely that our results may 
be an overestimation of smoking cessation rates and such rates in younger populations are unclear 
and warrant future research.  Particular attention should be given to those presenting with their first 
episode psychosis.  Fifth, details regarding the type and nature of smoking cessation advice were 
limited in the original manuscripts and it is unclear how heterogeneous these interventions were.  
Lastly, a number of the included studies appeared to demonstrate lower levels of mental illness than 
one would expect.  Thus, the samples of some studies may be biased to some extent.   
 
Future Research 
Future research should seek to investigate if there are differences in the rates of smoking cessation 
advice given to people that are newly diagnosed with a mental illness. Of great importance is 
prospective research to investigate the most effective type of smoking cessation advice on quitting 
rates in patients with mental illness and their health outcomes. Such research should inform clinical 
practice.  In particular, research is warranted to investigate smoking cessation advice rates and 
outcomes in younger people with mental illness.  
Conclusion 
People with severe mental illness are not offered any higher rates of smoking cessation advice to 
members of the general population without severe mental illness. People with mild mental illness 
appear to be offered slightly higher rates of smoking cessation.  This is despite the 2-4 higher rates of 
smoking in people with mental illness and the drastically increased morbidity and mortality 
attributed to tobacco use.  Clinicians should be given training about smoking cessation advice in this 
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population, and prevention and treatment of tobacco dependence should receive a higher priority in 
everyday clinical care.   
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Figure 1. PRISMA 2009 flow diagram for search strategy 
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Figure 2a – Pooled smoking cessation advice rates across included studies (N=7, n=721,658) 
 
Figure 2b, funnel plots for main pooled analysis  
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Figure 3. Smoking cessation rates in people with SMI and controls (N=5, n=559,122) 
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Figure 4. Pooled analysis of smoking cessation rates in people with non severe mental illness 
compared to those without any mental illness (n= mental illness=64,689, n control=515,517) 
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Study Design  
and 
locatio
n 
Details of 
participants 
Diagnosis 
of mental 
illness 
Details of 
smoking 
cessation 
Results 
smoking 
cessation 
attendance 
rates 
Other 
results 
NOS 
scor
e 
Druss et 
al. 2001 
 
USA, 
cross 
section
al, 
cohort 
study 
83,577 
Medicare 
patients 
hospitalised 
for a 
clinically 
confirmed 
Myocardial 
infarction 
without 
mental 
illness. 
Mean age 
76.1 years, 
52.7% 
female.  
 
4664 had a 
mental 
illness, 
mean age 
76 years, 
47% female.  
Any mental 
illness 
physician 
diagnosed 
Smoking 
cessation 
counselling 
documente
d during 
hospitalisati
on  
RR 1.03 (CI: 
0.95-1.12) 
 
 
Significant 
reduction 
in mortality 
among 
across the 
sample 
(including 
those with 
mental 
illness) in 
receipt of 
smoking 
cessation 
HR, 0.67 
(CI: 0.62-
0.72). 
7 
Hippisley
-Cox et 
al 2007 
 
UK, 
cross 
section
al, 
cohort 
study 
127 231 
patients 
with CHD 
and no 
mental 
illness, 
40.8% 
female.  
 
332 
patieŶt͛s 
schizophreni
a and CHD, 
47.3% 
female, 
86%>55 
years 
 
369 with 
bipolar 
disorder and 
CHD, 57.7% 
female, 
Schizophren
ia and 
bipolar 
disorder 
based on 
GP records 
Reported in 
smoking 
cessation 
status 
based on 
GP records 
in previous 
15 months.   
Schizophren
ia:  
RR 0.99 (CI: 
0.95-1.04) 
 
Bipolar 
disorder: 
RR 1.04 
(CI:1.01-
1.07) 
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94%>55 
years.   
 
 
Whyte et 
al 2007 
 
UK, 
cross 
section
al, 
cohort 
study  
10,000 
randomly 
selected 
from 
114,088 - 
patients 
with 
diabetes 
and no 
mental 
illness. 
45.1% 
female, 
median age 
67 (17 to 
101) years 
 
1043 people 
with SMI 
and 
diabetes 
(705 
schizophreni
a and 396 
bipolar 
disorder & 
58 had 
both), 53.8% 
female,  
median age 
62 (23 to 
93) years  
GP records 
SMI (bipolar 
disorder 
and 
schizophren
ia) 
Smoking 
cessation 
advice given 
over the 
past 15 
months as 
recorded on 
GP 
database.   
RR 1.52 (CI: 
0.6-3.86) 
97% of 
people with 
SMI had 
smoking 
cessation 
advice 
compare to 
96% of 
general 
population.   
8 
Goldberg 
et al 
2007 
 
USA, 
cross 
section
al study 
99 patients 
with 
diabetes 
and no 
mental 
illness, 53.1 
years, 47% 
female 
 
201 patients 
with SMI 
and 
diabetes 
50.1 years, 
52% female 
Medical 
records 
Smoking 
cessation 
counselling.  
RR 1.96 (CI: 
0.97-3.95) 
40.3% 
(n=42/104) 
people with 
SMI 
compared 
to 20.5% 
(n=7/34) 
without 
received 
smoking 
cessation 
counselling. 
6 
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(100 
schizophreni
a and 101 
major mood 
disorder) 
Szatkows
ki & 
McNeill, 
2013 
 
UK, 
cross 
section
al, 
cohort 
study 
387,246 
patieŶt͛s 
primary care 
without 
mental 
illness or 
taking 
psychotropi
c 
medication 
who 
smoked.  
Demographi
cs not 
available.  
 
32,154patie
nts with 
mental 
illness who 
smoked: 
 
Schizophren
ia 690  
BPD  398 
Depression 
19,754 
Neurotic, 
stress 
related 
somatoform 
disorders 
13,703 
Eating 
disorders 
244 
Personality 
disorders 
322 
Hyperkinetic 
disorders 
ADHD 75 
 
Medical 
records  
Smoking 
cessation 
advice 
offered.   
Whole 
sample:  
RR 1.45 (CI: 
1.43-1.48) 
 
Schizophren
ia 1.91 (CI: 
1.69-2.15) 
 
Bipolar 
disorder RR 
1.89 (CI: 
1.617-2.21) 
 
Depression 
RR 1.48 (CI: 
1.45-1.52) 
 
Neurotic, 
stress 
related 
somatoform 
disorders 
RR 1.46 (CI: 
1.42-1.51) 
 
Eating 
disorders 
RR 0.92(CI: 
0.71-1.19) 
 
Personality 
disorders 
RR 1.50 (CI: 
1.24-1.81) 
 
Hyperkineti
c disorders 
ADHD RR 
1.03 (CI: 
0.66-1.62) 
 
 
Prescriptio
n of 
smoking 
cessation 
medication 
higher in 
mental 
illness at 
11.2% 
compared 
to 6.73% in 
those 
without 
mental 
illness.   
 
Smoking 
cessation 
advice 
offered in 
lower 
proportion 
of 
consultatio
n in people 
with 
mental 
illness vs 
non mental 
illness; 
7.9% of 
consultatio
ns with 
smokers 
with a 
mental 
health 
diagnosis 
vs. 8.2% in 
non- 
mental 
illness.   
8 
Duffy et 
al 2012 
 
USA, 
cross 
section
27,652 
smokers 
without a 
Medical 
records 
Physicians 
gave advice 
on smoking 
Schizophren
ia   
RR 0.69 (CI: 
Significantl
y more 
people with 
7 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
al  mental 
illness. 
 
1430 
schizophreni
a smokers  
1612, 
bipolar 
disorder  
450 other 
psychosis  
11,068 
depression  
6,071 PTSD  
7,520 
substance 
user 
disorder. 
 
In eligible 
sample of 
smokers, 
24.8% were 
female v 
18.6% males 
cessation.  0.58-0.82) 
Bipolar 
RR 0.79 (CI: 
0.87-1.01) 
Other 
Psychosis 
RR 0.98 (CI: 
0.91-1.04) 
Depression 
RR 1.00 (CI: 
0.99-1.02) 
PTSD 
RR 1.02 
(0.99-1.03) 
Substance 
Use 
disorder 
RR 1.04 (CI: 
1.02-1.05) 
mental 
illness were 
smokers. 
Schizophre
nia OR 1.8, 
bipolar 
disorder OR 
1.5, 
depression 
OR 1.2, 
substance 
use 
disorders 
OR 2.7.  
Shi et al 
2014 
 
USA, 
cross 
section
al 
17,042 
people with 
mental 
illness  
 
 
1,897 with 
mental 
health 
problem. 
Had seen a 
mental 
health 
professional 
(Psychiatrist
, 
psychologist
) in past 
year 
Smoking 
cessation, 
advised to 
quit over 
the past 
year.  
RR 1.22 (CI: 
1.17-1.26) 
 6 
Key: GP= general practitioner, NOS score = Newcastle Ottawa Scale Score, CI= confidence interval, 
CHD= coronary heart disease, PTSD= post traumatic distress disorder, USA= united states of 
America, UK= United Kingdom, RR= relative risk, OR = odds ratio, HR=hazard ratio 
Note – All CI are reported at 95% unless otherwise stated.  
